Get the Stockscreener App
66.10
0.41%
0.27
After Hours:
66.10
Incyte Corp stock is traded at $66.10, with a volume of 1.60M.
It is up +0.41% in the last 24 hours and up +0.67% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$65.83
Open:
$65.4
24h Volume:
1.60M
Relative Volume:
0.74
Market Cap:
$12.72B
Revenue:
$3.86B
Net Income/Loss:
$97.30M
P/E Ratio:
34.97
EPS:
1.89
Net Cash Flow:
$-139.52M
1W Performance:
+3.09%
1M Performance:
+0.67%
6M Performance:
+16.03%
1Y Performance:
+14.42%
1-Day Range:
$65.27
$66.96
1-Week Range:
$62.57
$66.96
52-Week Range:
$50.27
$70.36
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte Corp. stock rises Monday, still underperforms market - MarketWatch
Incyte's SWOT analysis: biotech firm faces patent cliff, pipeline potential - Investing.com
Incyte Co. (NASDAQ:INCY) Short Interest Down 10.7% in September - MarketBeat
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Is Incyte Stock Underperforming The Nasdaq? - Barchart
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte Gains 12.7% Year To Date: How Should You Play The Stock? - Barchart
Incyte Gains 12.7% Year to Date: How Should You Play the Stock? - Yahoo Finance
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress - Yahoo Finance
Seven Eight Capital LP Sells 17,969 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top - MSN
Profund Advisors LLC Has $3.20 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $12.42 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Incyte Co. (NASDAQ:INCY) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte To Present At Cantor Global Healthcare Conference; Webcast At 9:45 AM ET - Nasdaq
Texas Permanent School Fund Corp Sells 7,699 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
FDA approves Niktimvo for chronic GVHD treatment - Investing.com
Incyte Co. (NASDAQ:INCY) Short Interest Down 8.2% in August - MarketBeat
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease - Yahoo Finance
Incyte lifts northern Delaware office vacancy rates - Delaware Business Times
Incyte DowngradedAnalyst Notes Intense Competition, Particularly In Larger Markets - Yahoo Finance
Incyte stock downgraded amid looming patent cliff concerns - Investing.com
Incyte downgraded at Truist on Jakafi patent cliff - Seeking Alpha
Incyte (NASDAQ:INCY) Stock Price Down 1.9% - MarketBeat
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
E Fund Management Co. Ltd. Purchases 9,733 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's (INCY) Market Perform Rating Reaffirmed at JMP Securities - MarketBeat
DekaBank Deutsche Girozentrale Sells 24,235 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Announces Promising New Data on Oncology Candidate at ESMO - Yahoo Finance
BofA raises Incyte stock target with Neutral rating on positive trial data - Investing.com
Incyte maintains Buy rating from TD Cowen post-ESMO data - Investing.com
Incyte (NASDAQ:INCY) Rating Reiterated by Cantor Fitzgerald - MarketBeat
Renaissance Technologies LLC Decreases Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Price Target Raised to $68.00 at Bank of America - MarketBeat
Incyte stock monitored as 'encouraging' trial results emergeGoldman Sachs - Investing.com
Forsta AP Fonden Has $4.13 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer - Yahoo Finance
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium - Yahoo Finance
Incyte Corp. stock rises Friday, still underperforms market - MarketWatch
Incyte Co. (NASDAQ:INCY) Shares Bought by Royal London Asset Management Ltd. - MarketBeat
Incyte Corp. stock rises Thursday, still underperforms market - MarketWatch
Incyte Corp. stock remains steady Wednesday, underperforms market - MarketWatch
Andra AP fonden Grows Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Endometrial Cancer Market Insights 2032 Report, Insights - openPR
Incyte Co. (NASDAQ:INCY) Shares Sold by Arizona State Retirement System - MarketBeat
Incyte Co. (NASDAQ:INCY) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Incyte Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Incyte shares maintain Buy rating on promising trial data - Investing.com
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):